Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2012 May 26

PMID 22628056

Citations 45

Authors

Lucas Sideris

Pierre Dube

Anja Rinke

Affiliations

Soon will be listed here.

Abstract

Background: For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect antitumor effects in secretory and nonsecretory NETs in addition to symptom control in secretory NETs.

Methods: A systematic review of MEDLINE was conducted to identify studies that investigated the antitumor effects of octreotide or lanreotide for patients with NETs. Additional studies not published in the peer-reviewed literature were identified by searching online abstracts. Results. In all, 17 octreotide trials and 11 lanreotide trials that included antitumor effects were identified. Partial response rates were between 0% and 31%, and stable disease rates were between 15% and 89%. Octreotide was the only somatostatin analog for which results of a phase III, randomized, placebo-controlled clinical trial that investigated antitumor effects were published. After 6 months of treatment in this randomized phase III trial, stable disease was observed in 67% of patients (hazard ratio for time to disease progression: 0.34; 95% confidence interval: 0.20-0.59; p = .000072).

Conclusions: In addition to symptom control for NETs, the data support an antitumor effect of somatostatin analogs and suggest that they may slow tumor growth. Long-acting repeatable octreotide has been shown to have an antitumor effect in a randomized phase III trial in midgut NETs, whereas results are pending in a corresponding controlled trial with lanreotide for patients with intestinal and pancreatic primary NETs.

Citing Articles

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs.

Ostios-Garcia L, Perez D, Castelo B, Herradon N, Zamora P, Feliu J Cancer Metastasis Rev. 2024; 43(4):1561-1571.

PMID: 38965194 PMC: 11554936. DOI: 10.1007/s10555-024-10188-5.

From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.

Melhorn P, Mazal P, Wolff L, Kretschmer-Chott E, Raderer M, Kiesewetter B Ther Adv Med Oncol. 2024; 16:17588359241240316.

PMID: 38529270 PMC: 10962050. DOI: 10.1177/17588359241240316.

Testicular neuroendocrine tumor in a 32-year-old man: A case report.

Dehghaniathar R, Moradi A, Emtiazi N Clin Case Rep. 2024; 12(3):e8620.

PMID: 38444924 PMC: 10912097. DOI: 10.1002/ccr3.8620.

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.

Pavel M, Lahner H, Horsch D, Rinke A, Denecke T, Koch A Oncologist. 2024; 29(5):e643-e654.

PMID: 38206830 PMC: 11067796. DOI: 10.1093/oncolo/oyad325.

Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.

Behdadnia A, Jeddi M J Med Case Rep. 2023; 17(1):400.

PMID: 37670372 PMC: 10481486. DOI: 10.1186/s13256-023-04042-5.

References

Clements D, Elias E . Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet. 1985; 1(8433):874-5. DOI: 10.1016/s0140-6736(85)92235-4. View

Arnold R, Trautmann M, Creutzfeldt W, Benning R, Benning M, Neuhaus C . Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996; 38(3):430-8. PMC: 1383075. DOI: 10.1136/gut.38.3.430. View

Faiss S, Pape U, Bohmig M, Dorffel Y, Mansmann U, Golder W . Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa.... J Clin Oncol. 2003; 21(14):2689-96. DOI: 10.1200/JCO.2003.12.142. View

Tomassetti P, Migliori M, Corinaldesi R, Gullo L . Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000; 14(5):557-60. DOI: 10.1046/j.1365-2036.2000.00738.x. View

Shepherd J, Senator G . Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet. 1986; 2(8506):574. DOI: 10.1016/s0140-6736(86)90139-x. View

Vinik A, Woltering E, Warner R, Caplin M, ODorisio T, Wiseman G . NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010; 39(6):713-34. DOI: 10.1097/MPA.0b013e3181ebaffd. View

Aparicio T, Ducreux M, Baudin E, Sabourin J, de Baere T, Mitry E . Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001; 37(8):1014-9. DOI: 10.1016/s0959-8049(01)00073-9. View

Kulke M, Siu L, Tepper J, Fisher G, Jaffe D, Haller D . Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011; 29(7):934-43. PMC: 3068065. DOI: 10.1200/JCO.2010.33.2056. View

Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, De Bellis A . Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol. 2008; 40(6):263-71. DOI: 10.1677/JME-08-0012. View

10.

Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656-63. DOI: 10.1200/JCO.2009.22.8510. View

11.

Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M . Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 1993; 32(2):217-23. DOI: 10.3109/02841869309083915. View

12.

Arnold R, Rinke A, Klose K, Muller H, Wied M, Zamzow K . Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005; 3(8):761-71. DOI: 10.1016/s1542-3565(05)00481-7. View

13.

Ricci S, Antonuzzo A, Galli L, Orlandini C, Ferdeghini M, Boni G . Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000; 23(4):412-5. DOI: 10.1097/00000421-200008000-00020. View

14.

Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P . Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer. 2006; 13(4):1213-21. DOI: 10.1677/erc.1.01200. View

15.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

16.

Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L . Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996; 77(2):402-8. DOI: 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4. View

17.

Chadha M, Lombardo J, Mashtare T, Wilding G, Litwin A, Raczyk C . High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009; 29(10):4127-30. View

18.

Rubin J, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R . Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999; 17(2):600-6. DOI: 10.1200/JCO.1999.17.2.600. View

19.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C . Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000; 11(9):1127-30. DOI: 10.1023/a:1008383132024. View

20.

Ducreux M, Ruszniewski P, Chayvialle J, Blumberg J, Cloarec D, Michel H . The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000; 95(11):3276-81. DOI: 10.1111/j.1572-0241.2000.03210.x. View